Objectives: An observational study to evaluate the relationship between serum concentrations of adalimumab and disease activity in patients receiving long-term adalimumab treatment for psoriatic arthritis. Methods: Serum adalimumab and adalimumab antidrug antibodies were quantified by enzyme linked immunosorbent assay. Disease activity was assessed using Disease Activity Score (44 joint measures). Serum C-reactive protein was quantified using standard methods. Results: A total of 30 patients were recruited. There were significant inverse correlations between serum adalimumab concentration and serum C-reactive protein (CRP) concentration [r = −0.43], the number of tender joints (r = −0.4), and Disease Activity Score (DAS44)-CRP (r = −0.36). Mean serum adalimumab levels were significantly higher in patients with DAS44-CRP <1.6 than in patients with DAS44-CRP ≥1.6. Conclusions: Serum adalimumab could be an important tool that may improve the management of psoriatic arthritis in patients responding to long-term treatment.

Chimenti, M.S., Triggianese, P., Narcisi, A., Marinari, B., Teoli, M., Faleri, S., et al. (2016). Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 44(1_suppl), 48-52 [10.1177/0300060515593235].

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response

CHIMENTI, MARIA SOLE;TRIGGIANESE, PAOLA;MARINARI, BARBARA;PERRICONE, ROBERTO;
2016

Abstract

Objectives: An observational study to evaluate the relationship between serum concentrations of adalimumab and disease activity in patients receiving long-term adalimumab treatment for psoriatic arthritis. Methods: Serum adalimumab and adalimumab antidrug antibodies were quantified by enzyme linked immunosorbent assay. Disease activity was assessed using Disease Activity Score (44 joint measures). Serum C-reactive protein was quantified using standard methods. Results: A total of 30 patients were recruited. There were significant inverse correlations between serum adalimumab concentration and serum C-reactive protein (CRP) concentration [r = −0.43], the number of tender joints (r = −0.4), and Disease Activity Score (DAS44)-CRP (r = −0.36). Mean serum adalimumab levels were significantly higher in patients with DAS44-CRP <1.6 than in patients with DAS44-CRP ≥1.6. Conclusions: Serum adalimumab could be an important tool that may improve the management of psoriatic arthritis in patients responding to long-term treatment.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/16 - Reumatologia
English
Adalimumab; anti-drug antibodies; disease activity; immunogenicity; psoriatic arthritis; tumour necrosis factor-α; Medicine (all); Biochemistry; Cell Biology; Biochemistry (medical)
http://imr.sagepub.com/content/by/year
Chimenti, M.S., Triggianese, P., Narcisi, A., Marinari, B., Teoli, M., Faleri, S., et al. (2016). Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 44(1_suppl), 48-52 [10.1177/0300060515593235].
Chimenti, Ms; Triggianese, P; Narcisi, A; Marinari, B; Teoli, M; Faleri, S; Arcese, A; Perricone, R; Costanzo, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/165601
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact